Erlotinib for advanced pancreatic cancer - Wikidata - awgldk - TriplyDB

Erlotinib for advanced pancreatic cancer

Erlotinib for advanced pancreatic cancer

http://www.wikidata.org/entity/Q24186983

about

Erlotinib for advanced pancreatic cancer

http://www.wikidata.org/entity/Q24186983

description

2015 nî lūn-bûn

@nan

2015 թուականի Յունուարին հրատարակուած գիտական յօդուած

@hyw

2015 թվականի հունվարին հրատարակված գիտական հոդված

@hy

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

name

Erlotinib for advanced pancreatic cancer

@ast

Erlotinib for advanced pancreatic cancer

@en

Erlotinib for advanced pancreatic cancer

@en-gb

Erlotinib for advanced pancreatic cancer

@nl

type

label

Erlotinib for advanced pancreatic cancer

@ast

Erlotinib for advanced pancreatic cancer

@en

Erlotinib for advanced pancreatic cancer

@en-gb

Erlotinib for advanced pancreatic cancer

@nl

prefLabel

Erlotinib for advanced pancreatic cancer

@ast

Erlotinib for advanced pancreatic cancer

@en

Erlotinib for advanced pancreatic cancer

@en-gb

Erlotinib for advanced pancreatic cancer

@nl

P1433

Q24186983-226F9FE9-6518-47D7-A2BD-C235C5F264FB

P1476

Q24186983-020AAD59-DE88-4E29-B799-13A3323A3562

P2093

Q24186983-1D1E25C9-EC28-4A2B-A0EE-C5D445024E06

Q24186983-2D1D2CB3-D2B4-4587-8A98-0943ABF63398

Q24186983-B1DF0BCE-1742-40C9-BA2F-E964315DBF62

Q24186983-E7F7726E-0C8C-4645-958C-3DAA0600DC67

Q24186983-F8237513-65A8-4DAE-A91C-BDCDB41D0E6C

P2860

Q24186983-0B87B612-CF05-40A1-B897-6A0668FBC406

Q24186983-0E98EBD4-753F-4100-9003-CA6EA5E7FF53

Q24186983-1503D7D6-3F9B-4EBB-BDA6-9050BE8B449B

Q24186983-1B93F282-0C5F-4044-88EF-7C8D32F3DA78

Q24186983-20BB7B44-8417-45AC-A02F-FC5B18FA5BE9

Q24186983-34A390D3-AD49-40D0-B800-ECD81BDB49B1

Q24186983-4028C83E-84C5-46A1-877A-4A90A3BC474B

Q24186983-66410925-D59A-4FC8-B627-2DB7251FCB09

Q24186983-6C899F45-58CC-4326-9310-BD457DB6482C

Q24186983-7420E11F-6AC5-4B28-9766-CF7120E2714C

P31

Q24186983-F8AFF9BE-3CA8-4C61-82FF-5012A23F0FE5

P356

Q24186983-D2472A53-D2D2-405F-8337-A0EED339B410

P50

Q24186983-5C31E8EA-877D-4D92-80E7-8F7388A322CC

P577

Q24186983-B776194E-7896-4BC0-941A-A5464E92C01F

P356

14651858.CD011463

P1433

Cochrane Database of Systematic Reviews

P1476

Erlotinib for advanced pancreatic cancer

@en

P2093

Elisa Giacomin

http://www.w3.org/2001/XMLSchema#string

Paolo Baldo

http://www.w3.org/2001/XMLSchema#string

Renato Cannizzaro

http://www.w3.org/2001/XMLSchema#string

Sara Balduzzi

http://www.w3.org/2001/XMLSchema#string

Sara Cecco

http://www.w3.org/2001/XMLSchema#string

P2860

Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints

Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial

FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer

Pancreatic cancer

Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine

Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group

Toxicity and response criteria of the Eastern Cooperative Oncology Group

A double-blind placebo-controlled, randomised study comparing gemcitabine and marimastat with gemcitabine and placebo as first line therapy in patients with advanced pancreatic cancer.

A phase III trial of pemetrexed plus gemcitabine versus gemcitabine in patients with unresectable or metastatic pancreatic cancer.

A phase I study of erlotinib in combination with gemcitabine and radiation in locally advanced, non-operable pancreatic adenocarcinoma.

P31

scholarly article

P356

10.1002/14651858.CD011463

http://www.w3.org/2001/XMLSchema#string

P50

Roberto D'Amico

P577

2015-01-10T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime